SFRS12IP1 Inhibitors

Chemical inhibitors of Splicing factor, arginine/serine-rich 12 interacting protein 1 (SFRS12IP1) can interfere with the protein's role in the splicing process through various mechanisms. Pladienolide B and its derivative E7107 directly bind to the SF3b complex, which is a core component of the spliceosome. By this action, they impede the spliceosome assembly, thereby inhibiting the splicing process in which SFRS12IP1 is involved. Similarly, Meayamycin and Spliceostatin A target the same SF3b complex, leading to a disruption in the splicing machinery. Madrasin also inhibits the spliceosome but may do so by affecting the function of other spliceosomal proteins, which in turn would disrupt the interaction of SFRS12IP1 within the complex, impeding its role in splicing.

Isoginkgetin acts by preventing spliceosome assembly, which is a prerequisite for the splicing reaction where SFRS12IP1 functions. Tetrocarcin A and Herboxidiene, also known as GEX1A, target the spliceosome and its associated processes. Their interaction with the splicing machinery hinders the proper functioning of the spliceosome, leading to an inhibition of the splicing activity where SFRS12IP1 is engaged. FR901464 operates by a similar mechanism, binding to the SF3b complex and thereby negatively affecting the splicing process. Placetin A, although less commonly known, also disrupts the spliceosomal function, which would inhibit the role of SFRS12IP1 in the splicing process. Homoharringtonine, while primarily recognized for its role in inhibiting protein synthesis, exerts an effect on splicing, which can indirectly inhibit the function of SFRS12IP1 by altering the spliceosome where it operates. Each of these chemicals, by targeting the spliceosome or its assembly, can impede the function of SFRS12IP1 in mRNA processing.